We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
After a brutal first-half, stocks have rebounded slightly this month as some investors believe that the sell-off could be reaching a bottom.
Per FT, hedge funds have started buying beaten-down biotech stocks, since they believe that ultra-cheap valuations could revive M&A activity in the space. Many big pharma companies are looking to boost their drug pipelines through acquisitions.
Biotech stocks were huge beneficiaries of the pandemic as many of these companies were developing new vaccines and treatments for Covid-19, leading to a surge in IPOs and venture capital investments.
After a brutal sell-off over the past year, some publicly traded biotech stocks have fallen so much that their market value is now below the amount of cash they have in the bank, per WSJ. M&A activity in the sector during the first half was at its lowest level in more than a decade.
The iShares Biotechnology ETF (IBB - Free Report) , the most popular product in the space, is market cap weighted. Amgen (AMGN - Free Report) , Vertex Pharmaceuticals (VRTX - Free Report) and Gilead Sciences (GILD - Free Report) are its top holdings.
The Invesco Nasdaq Biotechnology ETF (IBBQ - Free Report) tracks an index quite similar to IBB’s. It is much cheaper with an expense ratio of just 0.19%.
The SPDR S&P Biotech ETF (XBI - Free Report) tracks an equal weighted index and is tilted towards smaller companies.
The ARK Genomic Revolution ETF (ARKG - Free Report) is actively managed. Teladoc Health (TDOC - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are among its top holdings.
Please watch the short video above to lean more.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Should You Buy Beaten-Down Biotech Stocks & ETFs?
After a brutal first-half, stocks have rebounded slightly this month as some investors believe that the sell-off could be reaching a bottom.
Per FT, hedge funds have started buying beaten-down biotech stocks, since they believe that ultra-cheap valuations could revive M&A activity in the space. Many big pharma companies are looking to boost their drug pipelines through acquisitions.
Biotech stocks were huge beneficiaries of the pandemic as many of these companies were developing new vaccines and treatments for Covid-19, leading to a surge in IPOs and venture capital investments.
After a brutal sell-off over the past year, some publicly traded biotech stocks have fallen so much that their market value is now below the amount of cash they have in the bank, per WSJ. M&A activity in the sector during the first half was at its lowest level in more than a decade.
The iShares Biotechnology ETF (IBB - Free Report) , the most popular product in the space, is market cap weighted. Amgen (AMGN - Free Report) , Vertex Pharmaceuticals (VRTX - Free Report) and Gilead Sciences (GILD - Free Report) are its top holdings.
The Invesco Nasdaq Biotechnology ETF (IBBQ - Free Report) tracks an index quite similar to IBB’s. It is much cheaper with an expense ratio of just 0.19%.
The SPDR S&P Biotech ETF (XBI - Free Report) tracks an equal weighted index and is tilted towards smaller companies.
The ARK Genomic Revolution ETF (ARKG - Free Report) is actively managed. Teladoc Health (TDOC - Free Report) and CRISPR Therapeutics (CRSP - Free Report) are among its top holdings.
Please watch the short video above to lean more.